primary

Zarminali Pediatrics Welcomes New Chief Technology Officer to Advance Patient-Centric Connected Care Model

CHICAGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide elevated, seamlessly coordinated…

1 week ago

London School Joins Always Active Uniform Pilot to Combat Childrens Inactivity and Obesity Levels

Wednesday 1 October, 2025 Reception pupils at Harbinger Primary School received free movement friendly uniforms and activity bands to boost…

2 weeks ago

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

1 month ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…

2 months ago

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to…

2 months ago

Global Active Cyber Insurance Leader Coalition Launches in France

With Capacity Provided by Allianz, Active Insurance is Now Available to Businesses up to €1 Billion in Revenue on a…

2 months ago

C2N Announces Major Global Expansion, Adds Six New International Partners

PrecivityAD2™ blood test now available in over seven additional countries with primary focus on regions with inadequate PET infrastructureST. LOUIS--(BUSINESS…

2 months ago

Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis

KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was…

2 months ago

FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…

3 months ago